arthritis
NICE recommends four treatments for arthritis in children
October 22, 2015Medical Communications, Research and Development NICE, arthritis, jia
UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …
NICE recommends four treatments for arthritis in children
October 22, 2015Medical Communications, Research and Development NICE, arthritis, jia
UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …
Novartis’s secukinumab meets Phase 3 goals
October 1, 2015Research and Development Novartis, Secukinumab, arthritis
Novartis has announced that its secukinumab medication for treatment of psoriatic arthritis (PsA), met its primary endpoint in the pivotal …
Humira biosimilar released in India
December 18, 2014Research and Development, Sales and Marketing Humira, India, Zydus Cadila, anti-inflammatory, arthritis, bioscience
Indian firm Zydus Cadila has launched the first biosimilar of AbbVie’s anti-inflammatory medicine Humira, the world’s biggest-selling drug. Used as …
NICE U-turn over Janssen arthritis drug
December 9, 2014Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab
NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …
Stelara hit by final NICE rejection
March 28, 2014Sales and Marketing Janssen, NICE, UK, arthritis, psoriatic, stelar
In final draft guidance released today NICE says it cannot recommend Janssen’s psoriatic arthritis drug Stelara. Specifically, the pricing watchdog …
Sanofi and UCB launch new partnership
March 11, 2014Research and Development, Sales and Marketing Sanofi, UCB, arthritis, autoimmune, partnership
Sanofi and UCB have announced a new partnership that will see the companies research and develop new medicines together. Specifically, …
AstraZeneca sells arthritis drug for $35 million
November 20, 2013Sales and Marketing AstraZeneca, RA, arthritis, horizon, vimovo
AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million. AZ retains …
Remicade copies set for European entry
July 1, 2013Sales and Marketing CHMP, Hospira, Janssen, Remicade, arthritis, biosimilar
Janssen’s Remicade could soon come under generic pressure after a landmark recommendation by the CHMP. South Korean biotech Celltrion and …
Roche’s RoActemra beats Humira in arthritis study
March 5, 2012Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis
Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …
Late stage trial boost for Pfizer’s arthritis drug tasocitinib
November 8, 2010JAK inhibitors, Pfizer, arthritis, tasocitinib
Pfizer’s rheumatoid arthritis treatment tasocitinib has met its two of its three primary endpoints in a phase III trial. Primary …
